StockNews.com Initiates Coverage on Trinity Biotech (NASDAQ:TRIB)

Analysts at StockNews.com initiated coverage on shares of Trinity Biotech (NASDAQ:TRIBGet Free Report) in a note issued to investors on Wednesday. The firm set a “hold” rating on the stock.

Trinity Biotech Price Performance

Shares of NASDAQ TRIB opened at $0.93 on Wednesday. Trinity Biotech has a 12-month low of $0.74 and a 12-month high of $3.55. The firm’s 50-day moving average is $0.93 and its two-hundred day moving average is $1.61. The company has a market capitalization of $5.89 million, a PE ratio of -0.41 and a beta of 1.01.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Trinity Biotech stock. Hunter Associates Investment Management LLC increased its position in Trinity Biotech plc (NASDAQ:TRIBFree Report) by 5.2% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 378,590 shares of the company’s stock after buying an additional 18,780 shares during the quarter. Hunter Associates Investment Management LLC’s holdings in Trinity Biotech were worth $334,000 as of its most recent filing with the Securities and Exchange Commission. Institutional investors own 78.97% of the company’s stock.

Trinity Biotech Company Profile

(Get Free Report)

Trinity Biotech plc acquires, together with its subsidiaries, develops, acquires, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market in the Americas and Ireland. The company offers clinical laboratory products, including diagnostic tests and instrumentation, which detects infectious diseases; sexually transmitted diseases consisting of syphilis and herpes; SARS-CoV-2; and epstein barr, measles, mumps, toxoplasmosis, cytomegalovirus, rubella, varicella and other viral pathogens, as well as products for the in-vitro diagnostic testing for haemoglobin A1c used in the monitoring and diagnosis of diabetes, and identifying those who are at a risk of developing diabetes.

Featured Articles

Receive News & Ratings for Trinity Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trinity Biotech and related companies with MarketBeat.com's FREE daily email newsletter.